News
AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary ...
4d
Zacks Investment Research on MSNAstraZeneca Meets All Key Goals in Phase III Hypertension StudyAstraZeneca AZN reported positive top-line results from a late-stage study evaluating the safety, tolerability and efficacy ...
Topline data were announced from a phase 3 trial that evaluated baxdrostat in patients with uncontrolled or treatment resistant hypertension.
In addition to taking medication, paying attention to these habits can help maintain healthy blood pressure levels..resistant ...
David’s blood pressure was dangerously high until he received specialized care and renal denervation at BIDMC’s Complex Hypertension Clinic. Read his story.
AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a ...
4d
MedPage Today on MSNNovel Cushing's Syndrome Drug Improves Hypertension, HyperglycemiaSAN FRANCISCO -- The investigational selective glucocorticoid receptor modulator relacorilant led to improvements in blood ...
“Baxdrostat BaxHTN Phase III trials on patients with uncontrolled or treatment-resistant hypertension demonstrated a ...
Struggling to control high BP? Learn about resistant hypertension, its causes, and expert-approved ways to manage it. Get ...
Baxdrostat meets primary and all secondary endpoints in BaxHTN phase III trial in patients with uncontrolled or treatment resistant hypertension: Cambridge, UK Wednesday, July 16, ...
In a new clinical practice guideline, the Endocrine Society advises universal screening of those with hypertension by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results